Recent Updates — GSK
The US FDA has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B in adults without cirrhosis who have suppressed viral DNA and surface antigen levels ≤3000 IU/ml. The approval is based on phase III B-Well trial data showing a 19% functional cure rate after six months of treatment, compared to less than 1% with standard care alone. A secondary analysis showed a 26% cure rate in patients with lower baseline antigen levels (≤1000 IU/ml). GSK licensed the first-in-class antisense oligonucleotide from Ionis Pharmaceuticals and will continue pursuing regulatory approvals globally.
GSK is a global biopharmaceutical company focused on vaccines, specialty medicines, and consumer healthcare.
Maya Martinez-Davis, President of US operations at GSK plc, acquired 9.837 notional American Depositary Shares (ADS) valued at $48.54 per share through the company's Executive Supplemental Savings Plan on September 8, 2026. This transaction was reported via Form 6-K on September 10, 2026. GSK plc is a global biopharmaceutical company that develops and markets vaccines, specialty medicines, and consumer healthcare products.
GSK plc announced plans to establish a new flagship R&D centre on the Cambridge Biomedical Campus in the UK, investing £400 million over three years. The 300,000 square foot facility will house more than 1,000 scientists and support research in Oncology, Respiratory, Hepatology, Vaccines, and HIV. The move involves vacating the Stevenage site by 2029 and upgrading laboratories in Ware to integrate drug development and commercial manufacturing. This investment aims to accelerate the R&D pipeline by leveraging the local biomedical ecosystem. GSK is a global biopharma company focused on vaccines, specialty medicines, and consumer healthcare.
GSK plc’s licensor, Hansoh Pharma, announced positive results from the ARTEMIS-011 phase III trial for risvutatug rezetecan (Ris-Rez) in China. The study met its primary endpoint of progression-free survival in patients with relapsed osteosarcoma, demonstrating statistically significant and clinically meaningful improvements compared with chemotherapy. Consistent benefits were observed in overall survival, with no new safety signals identified. These data will support a regulatory submission in China. GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan, and is advancing the asset in global trials for sarcomas, lung cancer, and prostate cancer. Ris-Rez has received US FDA Breakthrough Therapy Designation for relapsed or refractory osteosarcoma. GSK plc is a global biopharmaceutical company focused on vaccines, specialty medicines, and consumer healthcare.